Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...
2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...
2023-11-13 20:41:53 ET More on Genfit Genfit GAAP EPS of -€0.42, revenue of €15.37M Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit For further details see: Genfit st...
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) Canada NewsWire Bylvay (odevixibat) is the first and only oral treatment available in Canada ...
2023-11-08 05:19:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American D...
2023-10-26 03:55:25 ET More on Ipsen S.A., Ipsen S.A., etc. Exelixis lead product hits main goal in Phase 3 prostate cancer trial Ipsen wins FDA approval of rare bone disease drug palovarotene Historical earnings data for Ipsen S.A. Dividend scorecard for Ips...
2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...